The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer

Najla M. Andisha[a,b,*], Donald C. McMillan[a], Fadia J.A. Gujam[a,b], Antonia Roseweir[b], Joanne Edwards[b]

[a] Academic Unit of Surgery, College of Medical, Veterinary and Life Sciences-University of Glasgow, Royal Infirmary, Glasgow, UK
[b] Unit of Gastrointestinal cancer and Molecular Pathology, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences-University of Glasgow, Glasgow, UK

ARTICLE INFO

ABSTRACT

Background: Despite advances in therapies to treat breast cancer, over 100,000 patients die in the UK of this disease per year, highlighting the need to develop effect predictive and prognostic markers for patients with primary operable ductal breast cancer. Therefore, the aim of the present study was to examine the relationship between membranous, cytoplasmic and nuclear expression of focal adhesion kinase (phosphorylated at Y 397, Y 861 and Y 925), molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.

Methods: Four hundred and seventy-four patients presenting between 1995 and 1998 with primary operable ductal breast cancer were included in this study. Using tissue microarrays expression of membranous, cytoplasmic and nuclear tumour cell phosphorylation of FAK at Y^{397}, Y^{861} and Y^{925} was assessed, and associations with clinicopathological characteristics, tumour microenvironment and cancer-specific survival (CSS) were examined.

Results: No significant association was observed for ph-FAK Y^{861} with survival at all sites. However, high expression of membranous ph-FAK Y^{397} was associated with increased tumour grade ($P < .001$), molecular subtypes ($P < .001$), increased tumour necrosis ($P < .001$), high Klintrup–Mäkinen grade ($P < .001$), increased CD138+ plasma cells ($P = .031$), endocrine therapy ($P = .001$) and poor cancer specific survival ($P = .040$). Similarly, high expression of nuclear ph-FAK Y^{397} was associated with decreased age ($P = .042$), increased CD138+ plasma cells ($P = .001$) and poor cancer specific survival ($P = .003$). Furthermore, high expression of cytoplasmic ph-FAK Y^{925} was associated with decreased tumour grade ($P < .001$), less involved lymph node ($P = .020$), molecular subtypes ($P < .001$), decreased tumour necrosis ($P < .001$), low Klintrup–Mäkinen grade ($P < .001$), decreased CD4+ T-cells ($P = .006$), decreased CD138+ plasma cells ($P = .034$), endocrine therapy ($P < .001$), chemotherapy ($P = .048$), and improved cancer specific survival ($P = .044$). On multivariate analysis, high expression of nuclear ph-FAK Y^{397} was independently associated with reduced cancer specific survival ($P = .017$).

Conclusion: The results of the present study show that membranous and nuclear ph-FAK Y^{397} and cytoplasmic ph-FAK Y^{925} were associated with prognosis in patients with primary operable ductal breast cancer. In addition, high expression of nuclear ph-FAK Y^{397} was an independent prognostic factor in patients with primary operable ductal breast cancer and could be incorporated into clinical practice.

1. Introduction

Breast cancer is a heterogeneous disease and is the most common cancer in females worldwide. In the UK, breast cancer is the second most common cancer representing 30% of all female cancers. Despite the routine use of hormone receptor status [1], TNM staging system [2],

---

* Corresponding author at: Academic Unit of Surgery, University of Glasgow, Glasgow Royal Infirmary, 2nd Floor, New Lister Building, 10-16 Alexandra Parade, Glasgow G31 2ER, UK.
  E-mail address: n.andisha.1@research.gla.ac.uk (N.M. Andisha).

and the recent introduction of molecular subtypes to identify likely outcomes and plan treatment, it is clear such staging approaches are suboptimal and require refinement.

Recently, there has been an increasing interest in studying the tumour microenvironment and how it affects disease outcome. Indeed, it is clear that the interaction between the tumour and its microenvironment are crucial for long-term survival. In breast cancer, many studies have highlighted the association between components of the tumour microenvironment and patient survival [3–5]. In particular, some phenotypic features such as the local inflammatory infiltrate and stromal infiltrate have recently been reported to have independent prognostic value in patients with primary operable ductal breast cancer [6–8]. Therefore, there is now increasing interest in the signalling transduction pathways that may be important in regulating such important phenotypic features.

Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that plays a critical role in cell motility and undergoes intracellular activation by multiple factors, such as Src Kinase, phospholipase and growth-factor-receptor-bound protein-7 [9]. In human cancers, increased tumour expression of FAK has been shown in several cancer types including lung, cervical and colon cancer when compared to normal tissue [10–12]. Phosphorylation of FAK at Y^{397} although not a measure of full activation itself, is a surrogate measure of activation and is associated with enhanced tumour growth, migration, invasion, adhesion and spreading, as well as tumour angiogenesis through regulation of both cancer cells and their microenvironment [13–15]. In two studies of > 1800 patients with breast cancer, total FAK expression was significantly associated with neoangiogenesis and reduced cancer specific survival [16,17]. Indeed, it has been reported that nuclear FAK regulates the anti-tumour immune response [18]. Moreover, autophosphorylation of FAK at Y^{397} allows binding of Src Kinase or other substrates such as ERK and PI3K to promote tumorigenesis [15,19]. Once auto-phosphorylated, phosphorylation of FAK Y^{861} can occur via Src [20] and phosphorylation of FAK Y^{925} can occur via ERK [21] to mediate distinct downstream effects.

In the last decade, a number of studies have documented the role of total FAK in many types of cancer including breast cancer [10–12]. However, there is less information about the role of phosphorylated form at each site (membranous, cytoplasmic and nuclear). Therefore, it was of interest to examine in more detail expression of ph-FAK Y^{397} (auto-phosphorylation) and ph-FAK Y^{861} (Src dependent phosphorylation) at different sites and highlight the relationship of each phosphorylation site individually with clinicopathological characteristic to provide novelty to our work.

Therefore, the aim of the present study was to examine relationship between phosphorylated membrane, cytoplasmic and nuclear FAK at Y^{397} (ph-FAK Y^{397}), Y^{861} (ph-FAK Y^{861}), and Y^{925} (ph-FAK Y^{925}), molecular subtypes, the tumour microenvironment and cancer specific survival in patients with primary operable ductal breast cancer.

2. Patients and methods

2.1. Patient cohort

Patients presenting with primary operable ductal breast cancer at Glasgow Royal and Western Infirmaries and Stobhill Hospital, in the West of Scotland, between 1995 and 1998 that had formalin-fixed paraffin embedded blocks of the primary tumour available for evaluation were studied ($n = 474$). The tissue was obtained from the Glasgow Biorepository and was approved by the Research Ethics Committee of the West Glasgow University Hospitals NHS Trust (REC reference 07/s0704/61). Individual patient consent was not required for this study.

2.2. Clinical and pathological characteristics

Clinicopathological data included age, tumour size, tumour grade,

lymph node status, type of surgery, and type of adjuvant therapy (chemotherapy, hormonal therapy and/or radiotherapy) was retrieved from the routine reports. Tumour grade was assigned according to Nottingham Grading System. Specific information on DCIS and on the resection margin status in this patient cohort was not available. ER and PR status were assessed on tissue microarrays (TMAs) using immunohistochemistry (IHC) and scored according to the American Society of Clinical Oncology and College of American Pathologists guidelines with cut-off value of 1% positive tumour nuclei [22]. HER-2 status were assessed visually using TMA sections as previously described i.e. a score $3+$ is regarded as positive; $2+$ is regarded as equivocal, leading to referral for HER-2 FISH; and 0 and $1+$ are regarded as negative [23].

Proliferation index was assessed by Ki-67 IHC using established protocols in the Department of Pathology, Glasgow Royal Infirmary with appropriate positive and negative controls [24]. Blood (BVI) and lymph (LVI) vessel invasion were assessed, on 2.5 μm thick sections, using IHC staining with the lymphatic endothelial marker D2–40 (SIG-3730, Covance, USA) diluted 1:100 and vascular endothelial marker Factor VIII (Leica, UK) diluted 1:100 as previously described [25]. Patients were routinely followed up after surgery. Date and cause of death was cross-checked with the cancer registration system and the Registrar General (Scotland). Death records were complete until 31st of May 2013 and that served as the censor date. Cancer-specific survival was measured from the date of primary surgery until the date of death from breast cancer.

2.3. Assessment of the tumour microenvironment

Full-section haematoxylin and eosin (H&E) slides taken at the deepest point of invasion were used to score local inflammatory infiltrate according to Klintrup Mäkinen (KM) grade as previously described [6]. Briefly, the inflammatory cell infiltrate at the invasive margin was classified as either low-grade (no increase or mild/patchy increase in inflammatory cells) or high-grade (prominent inflammatory reaction forming a band at the invasive margin, or florid cup-like infiltrate). Individual immune cells type was assessed using IHC staining on TMA sections for helper and cytotoxic T-lymphocytes, macrophages and plasma cells using CD4+, CD8+, CD68+ and CD138+ staining as previously described [26]. Full-section H&E slides were also used to score the tumour stroma percentage (TSP) and tumour budding as previously reported [8,27]. Briefly, a single field was examined for TSP and graded as either low ($\leq 50\%$) or high ($> 50\%$) and 5 fields were examined for budding and the highest bud count per field was used.

2.4. Immunohistochemistry

Immunohistochemical expression of ph-FAK Y^{397}, ph-FAK Y^{861} and ph-FAK Y^{925} was carried out using previously constructed tissue microarrays as previously reported [23]. TMAs contained 0.6-mm cores with three cores per patient and were sectioned at 2.5um thickness. TMA sections were dewaxed in histoclear before being rehydrated using graded alcohols. Antigen retrieval for ph-FAK Y^{397}, ph-FAK Y^{861} and ph-FAK Y^{925} was performed using Tris-EDETA buffer (pH 9) at 96 °C for 20 min before cooling. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 15 min for ph-FAK Y^{397}; 20 min for ph-FAK Y^{861} and 10 min for ph-FAK Y^{925}. Normal horse serum was applied for 60 min at 25 °C as a blocking solution. TMA sections were then incubated for 60 min at 25 °C with primary antibody for ph-FAK Y^{397} (ab39967, Abcam, UK) and ph-FAK Y^{861} (44-626G, Invitrogen, UK) at a concentration of 1:200. For ph-FAK Y^{925}, TMA sections were incubated with primary antibody (PA5–21148, SAB, UK) overnight at 4 °C at a 1:6000 dilution. Envision (Dako) secondary antibody was added for 30 min at room temperature. Proteins were visualized using DAB substrate then counterstained in haematoxylin and blued with Scotts' tap water before being dehydrated through a series of graded alcohols.

Fig. 1. (A) No expression. (B) High, moderate and low membranous expression. (C) High, moderate and low cytoplasmic expression. (D) High, moderate and low nuclear expression.

Cover slips were applied using distrene, plasticizer, xylene (DPX).

2.5. Scoring method

Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn Garden City, Hertfordshire, UK) at x20 magnification and visualized using Slidepath Digital Image Hub, version 4.0.1 (Leica Biosystems, UK). Assessment of tumour-specific membrane, cytoplasmic and nuclear ph-FAK Y^{397}, ph-FAK Y^{861} and ph-FAK Y^{925} expression was performed by two examiners (NMA and FJG) blinded to clinical data at x20 magnification (total magnification x400) using the weighted histoscore. The weighted histoscore provides an assessment of the percentage and density of staining and is calculated as follows: $0 \times \%$ not stained $+1 \times \%$ weakly stained $+2 \times \%$ moderately stained $+3 \times \%$ strongly stained as shown in Fig. 1A–D. This gives a range of scores from 0 to 300. To ensure reproducibility, 20% of tumours were co-scored by a second investigator; the intra-class correlation coefficient for all markers was > 0.70.

2.6. Statistical analysis

Patients were split into low and high expression using the median for all phosphorylation sites. Survival analysis was examined using Kaplan-Meier curves and the log-rank test. The relationships between FAK phosphorylation, molecular subtypes, and the tumour microenvironment were examined using the Chi-square test for linear trend. Univariate survival analysis was performed using Cox regression survival analysis to assess hazard ratios and 95% confidence intervals.

Multivariate survival analysis was performed using cox regression survival analysis using a backwards conditional method assessed independent prognostic factors along with common clinical and pathological factors. A P-value < .05 was considered statistically significant and the study conformed to the remark criteria. All analysis was performed using SPSS version 24.0 (IBM SPSS IL, USA).

3. Results

The majority of patients were older than 50 years (71%), had tumours size ≤2 cm (58%), had grade II carcinoma (41%), no axillary lymph node involvement (53%), and had low Klintrup–Mäkinen grade (73%).

The correlation between tumour-specific ph-FAK Y^{397}, ph-FAK Y^{861}, and ph-FAK Y^{925} expression in patients with primary operable ductal breast cancer is presented in Table 1. Membranous ph-FAK Y^{397} expression correlated with cytoplasmic ph-FAK Y^{397} expression (P < .001), nuclear ph-FAK Y^{397} expression (P = .001), membranous ph-FAK Y^{861} expression (P < .001), cytoplasmic ph-FAK Y^{861} expression (P < .001), nuclear ph-FAK Y^{861} expression (P = .002), and membranous ph-FAK Y^{925} expression (P < .001). Cytoplasmic ph-FAK Y^{397} expression correlated with nuclear ph-FAK Y^{397} expression (P < .001), membranous ph-FAK Y^{861} expression (P = .002), cytoplasmic ph-FAK Y^{861} expression (P < .001), and nuclear ph-FAK Y^{861} expression (P < .001). Nuclear ph-FAK Y^{397} expression correlated with cytoplasmic ph-FAK Y^{861} expression (P = .002), nuclear ph-FAK Y^{861} expression (P < .001), membranous ph-FAK Y^{925} expression (P = .003), and nuclear ph-FAK Y^{925} expression (P = .019).

Table 1
The relationship between tumour ph-FAK Y^{397}, ph-FAK Y^{861}, and ph-FAK Y^{925} expression in patients with primary operable ductal breast cancer.

	Ph-FAK Y^{397} cytoplasmic expression	Ph-FAK Y^{397} nuclear expression	Ph-FAK Y^{861} membranous expression	Ph-FAK Y^{861} cytoplasmic expression	Ph-FAK Y^{861} nuclear expression	Ph-FAK Y^{925} membranous expression	Ph-FAK Y^{925} cytoplasmic expression	Ph-FAK Y^{925} nuclear expression
Ph-FAK Y^{397} membranous expression	0.513** <0.001	0.156** 0.001	0.337** <0.001	0.308** <0.001	0.152** 0.002	0.232** <0.001	−0.077 0.126	−0.007 0.883
Ph-FAK Y^{397} cytoplasmic expression		0.249** <0.001	0.157** 0.002	0.404** <0.001	0.215** <0.001	0.098 0.051	−0.014 0.781	0.037 0.459
Ph-FAK Y^{397} nuclear expression			0.047 0.344	0.151** 0.002	0.439** <0.001	0.149** 0.003	0.005 0.914	0.118* 0.019
Ph-FAK Y^{861} membranous expression				0.392** <0.001	0.163** 0.001	0.249** <0.001	0.055 0.271	−0.043 0.386
Ph-FAK Y^{861} cytoplasmic expression					0.380** <0.001	0.076 0.127	0.051 0.305	−0.080 0.108
Ph-FAK Y^{861} nuclear expression						0.171** 0.001	0.092 0.069	0.075 0.136
Ph-FAK Y^{925} membranous expression							−0.036 0.448	0.010 0.827
Ph-FAK Y^{925} cytoplasmic expression								0.158** 0.001

** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).

Membranous ph-FAK Y^{861} expression correlated with cytoplasmic ph-FAK Y^{861} expression ($P < .001$), nuclear ph-FAK Y^{861} expression ($P = .001$), and membranous ph-FAK Y^{925} expression ($P < .001$). Cytoplasmic ph-FAK Y^{861} expression correlated with nuclear ph-FAK Y^{861} expression ($P < .001$). Nuclear ph-FAK Y^{861} expression correlated with membranous ph-FAK Y^{925} expression ($P = .001$). Cytoplasmic ph-FAK Y^{925} expression correlated with nuclear ph-FAK Y^{925} expression ($P = .001$). When assessing the correlation coefficients (CC), correlations between cytoplasmic ph-FAK Y^{397} and both membranous ph-FAK Y^{397} expression (CC = 0.513) and cytoplasmic ph-FAK Y^{861} (CC = 0.404), and between nuclear ph-FAK Y^{397} and nuclear ph-FAK Y^{861} (CC = 0.439) were considered as significant (CC > 0.4).

The median follow-up for alive patients ($n = 275$) was 150 months with 96 cancer-specific deaths and 90 non-cancer deaths. The relationship between tumour-specific ph-FAK Y^{397}, ph-FAK Y^{861}, ph-FAK Y^{925} expression and cancer specific survival (CSS) in the full cohort was examined as shown in Table 2 ($n = 474$). High expression of membranous ph-FAK Y^{397} was associated with reduced CSS ($P = .040$) (Fig. 2A) with 10-year survival reduced from 80% (low expression) to 71% (high expression). Similarly, high expression of nuclear ph-FAK Y^{397} was associated with reduced CSS ($P = .003$) (Fig. 2B) with 10-year survival reduced from 84% (low expression) to 72% (high expression). However, high expression of cytoplasmic ph-FAK Y^{925} was associated with increased CSS ($P = .044$) (Fig. 2C) with 10-year survival increased from 75% (low expression) to 83% (high expression). No other phosphorylation sites at any cellular location were associated with CSS (Fig. 3).

The relationship between tumour-specific phosphorylation, molecular subtypes, and the tumour microenvironment was assessed. High expression of membranous ph-FAK Y^{397} ($n = 419$; Table 3) was significantly associated with increased tumour grade ($P < .001$), molecular subtypes ($P < .001$), increased tumour necrosis ($P < .001$), high Klintrup–Mäkinen grade ($P < .001$), increased CD138 + plasma cells ($P = .031$), and endocrine therapy ($P = .001$). Whereas, high expression of nuclear ph-FAK Y^{397} ($n = 419$, Table 4) was associated with decreased age ($P = .042$), and increased CD138 + plasma cells ($P = .001$). However, high expression of cytoplasmic ph-FAK Y^{925} ($n = 443$; Table 5) was significantly associated with decreased tumour grade ($P < .001$), no involved lymph node ($P = .020$), molecular subtypes ($P < .001$), decreased tumour necrosis ($P < .001$), low Klintrup–Mäkinen grade ($P < .001$), decreased CD4+ T-cells, decreased CD138+ plasma cells ($P = .034$), endocrine therapy ($P < .001$), and chemotherapy ($P = .048$).

The relationship between FAK phosphorylation, clinicopathological characteristics and CSS is presented in Table 6 ($n = 474$). In univariate analysis, tumour size ($P < .001$), tumour grade ($P < .001$), involved lymph node ($P < .001$), molecular subtypes ($P < .001$), tumour necrosis ($P < .001$), tumour budding ($P < .001$), tumour stroma percentage ($P < .001$), Klintrup–Mäkinen grade ($P = .095$), CD8+ T-cells ($P = .004$), CD138+ plasma cells ($P = .003$), blood vessel invasion ($P < .001$), lymph vessel invasion ($P < .001$), membranous ph-FAK Y^{397} ($P = .042$), nuclear ph-FAK Y^{397} ($P = .003$), and cytoplasmic ph-FAK Y^{925} ($P = .046$) were associated with CSS. On multivariate analysis, involved lymph node ($P = .019$), molecular subtypes ($P = .009$), tumour necrosis ($P < .001$), tumour budding ($P = .005$), tumour stroma percentage ($P = .007$), CD8+ T-cells ($P \le .001$), CD138+ plasma cells ($P = .019$), blood vessel invasion ($P = .002$), lymph vessel invasion ($P = .023$), and nuclear ph-FAK Y^{397} ($P = .017$) were independent prognostic factors.

4. Discussion

The present study examined the level of phosphorylation of FAK at (tyrosine residue) Y^{397}, Y^{861}, and Y^{925} and assessed their relationship with clinicopathological characteristics, the tumour microenvironment and survival in patients with primary operable ductal breast cancer.

Table 2

The relationship between FAKs phosphorylation and survival in patients with primary operable ductal breast cancer ($n = 474$).

|	Membrane			Cytoplasmic			Nuclear		
	No	10 years. CCS	*P*-value	No	10 years. CCS	*P*-value	No	10 years. CCS	*P*-value
ph-FAK Y^{397}									
Low expression	322	80%	**.040**	213	77%	.448	206	84%	**.003**
High expression	97	71%		206	79%		12	72%	
ph-FAK Y^{861}									
Low expression	323	80%	.151	214	80%	.623	208	81%	.255
High expression	103	71%		212	76%		208	74%	
ph-FAK Y^{925}									
Low expression	359	81%	.139	239	75%	**.044**	415	78%	.109
High expression	85	70%		204	83%		29	93%	

A

B

C

Fig. 2. The association between FAK phosphorylation and cancer specific survival in patients with primary operable ductal breast cancer.
(A) Kaplan-Meier survival curve showing association between cancer specific survival and membranous ph-FAK Y^{397}.
(B) Kaplan-Meier survival curve showing association between cancer specific survival and nuclear ph-FAK Y^{397}.
(C) Kaplan-Meier survival curve showing association between cancer specific survival and cytoplasmic ph-FAK Y^{925}.

The study showed a significant correlation between membranous, cytoplasmic and nuclear ph-FAK Y^{397}, membranous, cytoplasmic and nuclear ph-FAK Y^{861}, and membranous ph-FAK Y^{925}, suggesting these sites may work together to regulated downstream pathways in these patients. Furthermore, membrane and nuclear ph-FAK Y^{397} associated with decreased survival whereas nuclear ph-FAK Y^{925} associated with improved survival. This suggests that FAK can differentially effect survival depending on the site of phosphorylation and highlights that

Fig. 3. Flow chart showing patient inclusion and exclusion criteria for study.

Y861 (CC = 0.439). A correlation coefficient (CC) between (0.40–0.59) may be considered to have a moderate correlation as reported in the bmj (Correlation and regression) [28].

In the current study, it was observed that high expression of membrane and nuclear ph-FAK Y^{397} were associated with outcome in early stage breast cancer. In addition, high expression of membrane ph-FAK Y^{397} was associated with increased tumour grade, molecular subtypes, increased tumour necrosis, low Klintrup–Mäkinen grade, increased CD138+ plasma cells, and endocrine therapy, suggesting it is associated with aggressive disease. In addition, high expression of nuclear ph-FAK Y^{397} was associated with decreased age and increased CD138+ plasma cells. Recently, Dwyer and co-workers have confirmed a role for FAK in NF-κB signalling and is associated with severe drop in the immune response, suggesting that auto-phosphorylation of FAK at Y397 can potentially modulate inflammation within the tumour microenvironment in patients with primary operable ductal breast cancer [29,30]. Based on the previous information, this may suggest that both canonical and non-canonical pathways are activated and this activation was significantly associated with inflammatory characteristics. However further work is required to substantiate this hypothesis.

In the present study, there was a significant association between membranous and nuclear ph-FAKY397 which may suggest that FAK moves to the nucleus once activated at this site to modulate the pro-tumorigenic inflammatory response. Interestingly, Lachowski and co-workers suggested that Yes-associated protein (YAP) translocates to the nucleus and become active under control of FAK [31]. Therefore, inhibiting phosphorylation at this site may improve survival in patients with primary operable ductal breast cancer. However further work is required to substantiate this hypothesis.

Compared with low, high phosphorylation of nuclear ph-FAK Y^{397} was significantly associated with poorer cancer specific survival. That may be due to nuclear ph-FAK Y^{397} promoting P53 degradation in the nucleus [32]. Therefore, overexpression of FAK in human tumour cells might contribute to malignancy by promoting survival under conditions that would normally lead to cell death. Indeed, Golubovskaya and co-workers have reported in a cell line study that inhibition FAK phosphorylation at Y^{397} and Y^{577} has been shown to have synergistic effects with inhibition of EGF-receptor signalling, leading to apoptosis in breast cancer cells [33,34]. More recently, it was reported that in 600 patients with breast cancer, the FAK promoter region contains p53 binding sites, and that p53 inhibits FAK transcription and regulates its expression in tumour samples. Furthermore, it was shown that FAK

each site needs to be investigated individually in patients with primary operable ductal breast cancer.

It has previously been shown that phosphorylation of FAK at tyrosine residue 861 (Y^{861}) is reliant on the auto phosphorylation of FAK at Y^{397}. Indeed, it has been reported that the auto-phosphorylation of FAK at Y 397 allows a conformational change that unmasks the binding site for Src kinase which, in turn, facilitates further phosphorylation of FAK at Y 861 [9]. Similarly, this auto phosphorylation may also lead to the unmasking of the Y^{925} site allowing phosphorylation at this site by ERK. To confirm this, it would be of interest to examine the association between ph-FAK Y^{397}, ph-FAK Y^{861}, and FAK Y^{925}.

In the present study, a correlation was observed from the scatter plots between cytoplasmic ph-FAK Y397 and both membranous ph-FAK Y397 expression (CC = 0.513) and cytoplasmic ph-FAK Y861 (CC = 0.404), and between nuclear ph-FAK Y397 and nuclear ph-FAK

Table 3
The relationship between membranous ph-FAK Y^{397} expression, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer (n = 419).

All patients (n = 419)	Patients	Low phosphorylation (n = 322)	High phosphorylation (n = 97)	P-value
Age ≤ 50/ > 50 years/ missed	128/291/0	99/223	29/68	.874
Tumour size (≤2, 2.1–5, > 5)/ / missed	240/168/11/0	196/115/11	44/53/0	.057
Tumour grade (I/II/III)/missed	75/164/180/0	67/133/122	8/31/58	< .001
Involved lymph node (negative/positive)/ missed	223/191/5	170/147	53/44	.861
Molecular subtypes (A, B, TN, HER-2)/ missed	194/102/73/30/12	161/80/49/13	33/22/24/17	< .001
Tumour necrosis (low/high)/missed	188/231/0	164/158	24/73	< .001
Tumour budding (low/high)/missed	268/151/0	205/117	63/34	.818
Tumour stroma percentage (low/high)/ missed	277/142/0	211/111	66/31	.647
Klintrup–Mäkinen grade (low/high)/ missed	298/121/0	244/78	54/43	< .001
CD4+ (low/moderate/high)/missed	177/86/148/8	136/67/112	41/19/36	.816
CD8+ (low/moderate/high)/missed	126/141/144/8	96/114/105	30/27/39	.490
CD68+ (low/moderate/high)/missed	118/145/147/9	85/114/116	33/31/31	.203
CD138+ (low/moderate/high)/missed	220/55/135/9	175/47/93	45/8/42	.031
Blood vessel invasion (yes/no)/ missed	368/51/0	284/38	84/13	.673
Lymph vessel invasion (no/yes)/ missed	280/139/0	217/105	63/34	.655
Endocrine therapy (no/yes)/missed	119/294/6	78/238	41/56	**.001**
Chemotherapy (no/yes)/missed	230/186/3	184/135	46/51	.076
Alive/cancer death/non cancer death/ missed	233/89/85/12	182/62/68	51/27/17	.866
Cancer specific survival (months)[a]/ missed	419/0	152 (146–158)	138 (125–151)	**.040**

[a] Means 95% CI.

Table 4

The relationship between nuclear ph-FAK Y^{397} expression, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer (n = 419).

All patients (n = 419)	Patients	Low phosphorylation (n = 206)	High phosphorylation (n = 213)	P-value
Age (≤ 50/ > 50 years)/ missed	127/291/1	53/153	74/138	**.042**
Tumour size (≤ 2, 2.1–5, > 5)/missed	231/164/11/13	112\86\8	127\82\3	.136
Tumour grade (I/ II/ III)/ missed	75/164/179/1	33/89/84	42/75/95	.973
Involved lymph node (negative/positive)/ missed	223/190/6	111/93	112/97	.867
Molecular subtypes (A, B, TN, HER-2)/ missed	194/102/72/30/21	98/51/31/15	96/51/41/15	.495
Tumour necrosis (low/high)/missed	188/230/1	98/108	90/122	.293
Tumour budding (low/high)/missed	267/151/1	136/70	131/81	.369
Tumour stroma percentage (low/high)/ missed	277/141/1	143/63	134/78	.180
Klintrup–Mäkinen grade (low/high)/ missed	298/120/1	154/52	144/68	.123
CD4+ (low/moderate/high)/missed	176/86/148/9	85/52/64	91/34/84	.418
CD8+ (low/moderate/high)/missed	125/141/144/9	57/70/74	68/71/70	.348
CD68+ (low/moderate/high)/missed	117/145/147/10	58/67/76	59/78/71	.688
CD138+ (low/moderate/high)/missed	219/55/135/10	119/34/48	100/21/87	**.001**
Blood vessel invasion (yes/no)/missed	367/51/1	181/25	186/26	.968
Lymph vessel invasion (no/yes)/missed	279/139/1	135/71	144/68	.604
Endocrine therapy (no/yes)/missed	118/294/7	55/147	63/147	.534
Chemotherapy (no/yes)/ missed	230/185/4	113/90	117/95	.922
Alive/cancer death/non cancer death/ missed	232/89/85/13	126/32/39	106/57/46	.356
Cancer specific survival (months)[a]/missed	419/0	157 (150–164)	141 (133–149)	**.003**

[a] Means 95% CI.

overexpression and p53 mutations are directly associated [35]. Therefore, from the present work, it is suggested that ph-FAK Y^{397} would present a rational therapeutic target in patients with primary operable ductal breast cancer, which is of particular interest now with many inhibitors entering clinical trials [36].

The results of the present study also show that high expression of cytoplasmic ph-FAK Y^{925} was significantly associated with decreased tumour grade, molecular subtypes, no involved lymph node, decreased tumour necrosis, low Klintrup–Mäkinen grade, decreased CD138 + plasma cells, endocrine therapy, chemotherapy, and better cancer specific survival. This suggests that cytoplasmic ph-FAK Y^{925} is not regulating the same downstream pathways as ph-FAK Y^{397}. This is not surprising as this site resides in the C terminal domain and provides binding sites for SH2 (Src homology-2) domain-containing proteins, whereas Y^{397} resides in the kinase domain [37–39]. Furthermore, this site is activated by ERK signalling pathway, which has previously been shown to be associated with improved survival and decreased inflammation suggesting that FAK can differentially regulate the inflammatory response depending on the sites phosphorylated [40–42].

The main limitation of the present study was that although there was extensive characterization of tumour and host characteristics these observations were cross-sectional in nature. Therefore, the associations observed may not be causal in effect. In addition, although there was 10-year follow-up of the patients, contemporary management of ductal breast cancer has changed over this period. Nevertheless, the present results provide important information pertaining to the importance of the FAK signal transduction pathways in the development of aggressive phenotypic characteristics in patients with primary operable ductal breast cancer.

In summary, the results of the present study showed that membranous and nuclear ph-FAK Y^{397}, and cytoplasmic ph-FAK Y^{925} were differentially associated with clinicopathological characteristic and survival but only nuclear ph-FAK Y^{397} was an independently prognostic factor in patients with primary operable ductal breast cancer. Therefore, nuclear ph-FAK Y^{397} could be a potential target in treatment of patients with primary operable ductal breast cancer. Furthermore, the results suggest it is important to know which site is phosphorylated and not just to look at a surrogate of FAK activation when assessing

Table 5

The relationship between cytoplasmic FAK Y^{925} expression, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer (n = 443).

All patients (n = 443)	Patients	Low phosphorylation (n = 239)	High phosphorylation (n = 204)	P-value
Age (≤ 50/ > 50 years)/ missed	126/317/0	68/171	58\146	.996
Tumour size (≤ 2, 2.1–5, > 5)/ missed	258/172/13/0	134/98/7	124\74\6	.373
Tumour grade (I/ II/ III)/ missed	85/180/178/0	37/83/119	48/97/59	< .001
Involved lymph node (negative/positive)/ missed	235/203/5	114/121	121/82	**.020**
Molecular subtypes (A,B, TN, HER-2)/ missed	213/109/71/28/22	101/48/57/20	112/61/14/8	< .001
Tumour necrosis (low/high)/ missed	209/234/0	91/148	118/86	< .001
Tumour budding (low/high)/ missed	287/156/0	160/79	127/77	.303
Tumour stroma percentage (low/high)/ missed	295/148/0	161/78	134/70	.709
Klintrup–Mäkinen grade (low/high)/ missed	322/121/0	155/84	176/37	< .001
CD4+ (low/moderate/high)/ missed	195/89/151/8	93/44/95	102/45/56	**.006**
CD8+ (low/moderate/high)/ missed	139/144/152/8	71/72/89	68/72/63	.194
CD68+ (low/moderate/high)/ missed	131/150/152/10	72/76/82	59/74/70	.891
CD138+ (low/moderate/high)/ missed	237/55/141/10	115/31/84	122/24/57	**.034**
Blood vessel invasion (yes/no)/ missed	390/53/0	208/31	182/22	.824
Lymph vessel invasion (no/yes)/ missed	302/141/0	163/76	139/65	.989
Endocrine therapy (no/yes)/ missed	117/318/8	85/150	32/168	< .001
Chemotherapy (no/yes)/ missed	250/190/3	125/113	125/77	**.048**
Alive/cancer death/non cancer death/ missed	251/93/86/13	128/59/46	123/34/40	.590
Cancer specific survival (months)[a]/missed	443/0	145(138–153)	156 (149–163)	**.044**

[a] Means 95% CI.

Table 6

Multivariate analysis of FAK phosphorylation, clinicopathological characteristics and cancer specific survival in patients with primary operable ductal breast cancer ($n = 474$).

All patients ($n = 474$)	Univariate analysis		Multivariate analysis	
	Hazard ratio (95% CI)	*P*-value	Hazard ratio (95% CI)	*P*-value
Age (≤ 50/ > 50 years)	1.22 (0.77–1.91)	.397		
Tumour size (≤ 2, 2.1–5, > 5)	2.11 (1.49–2.97)	< .001		.108
Tumour grade (I/ II/ III)	1.87 (1.38–2.53)	< .001		.458
Involved lymph node (negative/positive)	2.76 (1.80–4.23)	< .001	1.85 (1.11–3.10)	.019
Molecular subtypes (A, B, TN, HER-2)	1.49 (1.23–1.80)	< .001	1.35 (1.08–1.69)	.009
Tumour necrosis (low/high)	4.38 (2.65–8.24)	< .001	3.34 (1.77–2.30)	< .001
Tumour budding (low/high)	2.53 (1.69–3.79)	< .001	2.00 (1.23–3.24)	.005
Tumour-stroma percentage (low/high)	2. 19 (1.46–3.27)	< .001	1.86 (1.18–2.92)	.007
Klintrup–Mäkinen grade (low/high)	1.44 (0.94–2.19)	.095		.789
CD4+ (low/moderate/high)	0.96 (0.80–1.25)	.983		
CD8+ (low/moderate/high)	0.70 (0.54–0.89)	.004	0.55 (0.40–0.74)	< .001
CD68+ (low/moderate/high)	0.86 (0.67–1.10)	.222		
CD138+ (low/moderate/high)	1.38 (1.11–1.72)	.003	1.37 (1.05–1.79)	.019
Blood vessel invasion (no/yes)	3.39 (2.14–5.39)	< .001	2.28 (1.35–3.86)	.002
Lymph vessel invasion (no/yes)	4.14 (2.75–6.25)	< .001	1.85 (1.09–3.15)	.023
Membranous Ph-FAK Y ^{397}	1.60 (1.02–2.51)	.042		.495
Nuclear Ph-FAK Y^{397}	1.92 (1.25–2.97)	.003	1.76 (1.11–2.81)	.017
Cytoplasmic Ph-FAK Y^{925}	0.65 (0.43–0.99)	.046		.281

Different IHC staining for FAK expression at different localisations.

patient survival.

References

[1] J.D. Brenton, L.A. Carey, A.A. Ahmed, C. Caldas, Molecular classification and Molecular forecasting of breast cancer: ready for clinical application? J. Clin. Oncol. 23 (29) (2005 Oct 10) 7350–7360 Epub 2005 Sep 6. Review. PubMed PMID: 16145060.

[2] L.H. Sobin, I.D. Fleming, TNM classification of malignant tumours, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer, Cancer 80 (9) (Nov 1 1997) 1803–1804 PubMed PMID: 9351551.

[3] M.W. Conklin, P.J. Keely, Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers, Cell Adhes. Migr. 6 (3) (2012 May–Jun) 249–260, https://doi.org/10.4161/cam.20567 Epub 2012 May 1. Review. PubMed PMID: 22568982; PubMed Central PMCID: PMC3427239.

[4] K. Kontzoglou, V. Palla, G. Karaolanis, I. Karaiskos, I. Alexiou, I. Pateras, K. Konstantoudakis, M. Stamatakos, Correlation between Ki67 and breast cancer prognosis, Oncology 84 (4) (2013) 219–225, https://doi.org/10.1159/000346475 (Epub 2013 Jan 24. Review. PubMed PMID: 23364275).

[5] H. Matsumoto, S.L. Koo, R. Dent, P.H. Tan, J. Iqbal, Role of inflammatory infiltrates in triple negative breast cancer, J. Clin. Pathol. 68 (7) (2015 Jul) 506–510, https://doi.org/10.1136/jclinpath-2015-202944 Epub 2015 Mar 6. Review. PubMed PMID: 25750267.

[6] Z.M. Mohammed, J.J. Going, J. Edwards, D.C. McMillan, The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer, Cancer Treat. Rev. 38 (8) (2012 Dec) 943–955, https://doi.org/10.1016/j.ctrv.2012.04.011 Epub 2012 May 30. Review. PubMed PMID: 22651904.

[7] Z.M. Mohammed, J.J. Going, J. Edwards, B. Elsberger, D.C. McMillan, The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer, Br. J. Cancer 109 (6) (2013 Sep 17) 1676–1684, https://doi.org/10.1038/bjc.2013.493 Epub 2013 Aug 27. PubMed PMID: 23982600; PubMed Central PMCID: PMC3777002.

[8] F.J. Gujam, J. Edwards, Z.M. Mohammed, J.J. Going, D.C. McMillan, The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer, Br. J. Cancer 111 (1) (2014 Jul 8) 157–165, https://doi.org/10.1038/bjc.2014.279 Epub 2014 May 29. PubMed PMID: 24874480; PubMed Central PMCID: PMC4090742.

[9] S.K. Mitra, D.A. Hanson, D.D. Schlaepfer, Focal adhesion kinase: in command and control of cell motility, Nat. Rev. Mol. Cell Biol. 6 (1) (2005 Jan) 56–68 Review. PubMed PMID: 15688067.

[10] L.V. Owens, L. Xu, R.J. Craven, G.A. Dent, T.M. Weiner, L. Kornberg, E.T. Liu, W.G. Cance, Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors, Cancer Res. 55 (13) (1995 Jul 1) 2752–2755 PubMed PMID: 7796399.

[11] M.H. Oktay, K. Oktay, D. Hamele-Bena, A. Buyuk, L.G. Koss, Focal adhesion kinase as amarker of malignant phenotype in breast and cervical carcinomas, Hum. Pathol. 34 (3) (2003 Mar) 240–245 PubMed PMID: 12673558.

[12] H.F. Ji, D. Pang, S.B. Fu, Y. Jin, L. Yao, J.P. Qi, J. Bai, Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer, J. Cancer Res. Clin. Oncol. 139 (3) (2013 Mar) 429–435, https://doi.org/10.1007/s00432-012-1342-8 Epub 2012 Nov 11. PubMed PMID: 23143646.

[13] G.W. McLean, N.O. Carragher, E. Avizienyte, J. Evans, V.G. Brunton, M.C. Frame, The role of focal-adhesion kinase in cancer – a new therapeutic opportunity, Nat. Rev. Cancer 5 (7) (2005 Jul) 505–515 Review. PubMed PMID: 16069815.

[14] N.A. Chatzizacharias, G.P. Kouraklis, S.E. Theocharis, Clinical significance of FAKexpression in human neoplasia, Histol. Histopathol. 23 (5) (2008 May) 629–650 Review.PubMed PMID: 18283648.

[15] J. Zhao, J.L. Guan, Signal transduction by focal adhesion kinase in cancer, Cancer Metastasis Rev. 28 (1–2) (2009 Jun) 35–49, https://doi.org/10.1007/s10555-008-9165-4 Review. PubMed PMID: 19169797.

[16] C. Charpin, V. Secq, S. Giusiano, S. Carpentier, L. Andrac, M.N. Lavaut, C. Allasia, P. Bonnier, S. Garcia, A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays, Int. J. Cancer 124 (9) (2009 May 1) 2124–2134, https://doi.org/10.1002/ijc.24177 PubMed PMID: 19142869.

[17] S. Garcia, J.P. Dales, E. Charafe-Jauffret, S. Carpentier-Meunier, L. Andrac-Meyer, J. Jacquemier, C. Andonian, M.N. Lavaut, C. Allasia, P. Bonnier, C. Charpin, Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis, Int. J. Oncol. 31 (1) (2007 Jul) 49–58 PubMed PMID: 17549404.

[18] A. Serrels, T. Lund, B. Serrels, A. Byron, R.C. McPherson, A. von Kriegsheim, L. Gómez-Cuadrado, M. Canel, M. Muir, J.E. Ring, E. Maniati, A.H. Sims, J.A. Pachter, V.G. Brunton, N. Gilbert, S.M. Anderton, R.J. Nibbs, M.C. Frame, Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity, Cell 163 (1) (2015 Sep 24) 160–173, https://doi.org/10.1016/j.cell.2015.09.001 PubMed PMID: 26406376; PubMed Central PMCID: PMC4597190.

[19] M.D. Schaller, J.D. Hildebrand, J.D. Shannon, J.W. Fox, R.R. Vines, J.T. Parsons, Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src, Mol. Cell. Biol. 14 (3) (1994 Mar) 1680–1688 PubMed PMID: 7509446; PubMed Central PMCID: PMC358526.

[20] M.A. Westhoff, B. Serrels, V.J. Fincham, M.C. Frame, N.O. Carragher, SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling, Mol. Cell. Biol. 24 (18) (2004 Sep) 8113–8133 PubMed PMID: 15340073; PubMed Central PMCID: PMC515031.

[21] T.H. Lin, A.E. Aplin, Y. Shen, Q. Chen, M. Schaller, L. Romer, I. Aukhil, R.L. Juliano, Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts, J. Cell Biol. 136 (6) (1997 Mar 24) 1385–1395 PubMed PMID: 9087451; PubMed Central PMCID: PMC2132513.

[22] M.E. Hammond, D.F. Hayes, M. Dowsett, D.C. Allred, K.L. Hagerty, S. Badve, P.L. Fitzgibbons, G. Francis, N.S. Goldstein, M. Hayes, D.G. Hicks, S. Lester, R. Love, P.B. Mangu, L. McShane, K. Miller, C.K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, J.N. Schwartz, F.C. Sweep, S. Taube, E.E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R.B. Williams, J.L. Wittliff, A.C. Wolff, American Society of Clinical Oncology; College of American Pathologists, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version), Arch. Pathol. Lab. Med. 134 (7) (2010 Jul) e48–e72 10.1043/1543-2165-134.7. e 48. Review. PubMed PMID: 20586616.

[23] Z.M. Mohammed, J.J. Going, D.C. McMillan, C. Orange, E. Mallon, J.C. Doughty, J. Edwards, Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer, Histopathology 61 (4) (2012 Oct) 675–684, https://doi.org/10.1111/j.1365-2559.2012.04280. x PubMed PMID: 22747525.

[24] Z.M. Mohammed, D.C. McMillan, B. Elsberger, J.J. Going, C. Orange, E. Mallon, J.C. Doughty, J. Edwards, Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer, Br. J. Cancer 106 (2) (2012 Jan 17) 383–388, https://doi.org/10.1038/bjc.2011.569 Epub 2012 Jan 3. PubMed PMID: 22251968; PubMed Central PMCID: PMC326167.

[25] F.J. Gujam, J.J. Going, Z.M. Mohammed, C. Orange, J. Edwards, McMillan DC, Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer, BMC Cancer 14 (2014 Sep 18) 676, https://doi.org/10.1186/1471-2407-14-676 PubMed PMID: 25234410; PubMed Central PMCID: PMC4177173.

[26] K. Klintrup, J.M. Mäkinen, S. Kauppila, P.O. Väre, J. Melkko, H. Tuominen, K. Tuppurainen, J. Mäkelä, T.J. Karttunen, M.J. Mäkinen, Inflammation and prognosis in colorectal cancer, Eur. J. Cancer 41 (17) (2005) 2645–2654 Epub 18. PubMed PMID:16239109.

[27] F.J. Gujam, D.C. McMillan, Z.M. Mohammed, J. Edwards, J.J. Going, The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer, Br. J. Cancer 113 (7) (2015 Sep 29) 1066–1074, https://doi.org/10.1038/bjc.2015.287 Epub 2015 Aug 11. PubMed PMID: 26263482.

[28] The bmj. 11. Correlation and Regression at https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression

[29] S.F. Dwyer, L. Gao, I.H. Gelman, Identification of novel focal adhesion kinase substrates: role for FAK in NFκB signaling, Int. J. Biol. Sci. 11 (4) (2015 Feb 17) 404–410, https://doi.org/10.7150/ijbs.10273 e Collection 2015. PubMed PMID: 25798060; PubMed Central PMCID: PMC4366639.

[30] S.C. Sun, The non-canonical NF-κB pathway in immunity and inflammation, Nat. Rev. Immunol. 17 (9) (2017 Sep) 545–558, https://doi.org/10.1038/nri.2017.52 Epub 2017 Jun 5. Review. PubMed PMID: 28580957; PubMed Central PMCID: PMC5753586.

[31] D. Lachowski, E. Cortes, B. Robinson, A. Rice, K. Rombouts, Del Río Hernández AE. FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis, FASEB J. 32 (2) (2018 Feb) 1099–1107, https://doi.org/10.1096/fj.201700721R Epub 2018 Jan 3. PubMed PMID: 29070586.

[32] S.T. Lim, Nuclear FAK: a new mode of gene regulation from cellular adhesions, Mol. Cell 36 (1) (2013 Jul) 1–6, https://doi.org/10.1007/s10059-013-0139-1 Epub 2013 May 16. Review. PubMed PMID: 23686429; PubMed Central PMCID: PMC3887928.

[33] V. Golubovskaya, L. Beviglia, L.H. Xu, H.S. Earp 3rd, R. Craven, W. Cance, Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells, J. Biol. Chem. 277 (41) (2002 Oct 11) 38978–38987 Epub 2002 Aug 7. PubMed PMID: 12167618.

[34] L. Beviglia, V. Golubovskaya, L. Xu, X. Yang, R.J. Craven, W.G. Cance, Focal adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment and apoptosis, Biochem. J. 373 (Pt 1) (2003 Jul 1) 201–210 PubMed PMID: 12659633; PubMed Central PMCID: PMC1223465.

[35] V.M. Golubovskaya, W. Cance, Focal adhesion kinase and p53 signal transduction pathways in cancer, Front. Biosci. 15 (2010 Jun 1) 901–912 (Landmark Ed). Review. PubMed PMID: 20515733; PubMed Central PMCID: PMC3136041.

[36] V.M. Golubovskaya, Targeting FAK in human cancer: from finding to first clinical trials, Front. Biosci. 19 (2014 Jan 1) 687–706 (Landmark Ed). Review. PubMed PMID: 24389213; PubMed Central PMCID: PMC3952878.

[37] M.B. Calalb, T.R. Polte, S.K. Hanks, Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases, Mol. Cell. Biol. 15 (2) (1995 Feb) 954–963 PubMed PMID: 7529876 ; PubMed Central PMCID: PMC231984.

[38] D. Ilić, E.A. Almeida, D.D. Schlaepfer, P. Dazin, S. Aizawa, C.H. Damsky, Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis, J. Cell Biol. 143 (2) (1998 Oct 19) 547–560 PubMed PMID: 9786962 ; PubMed Central PMCID: PMC2132850.

[39] H. Yoon, J.P. Dehart, J.M. Murphy, S.T. Lim, Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights, J. Histochem. Cytochem. 63 (2) (2015 Feb) 114–128, https://doi.org/10.1369/0022155414561498 Epub 2014 Nov 7. Review. PubMed PMID: 25380750; PubMed Central PMCID: PMC4305513.

[40] T. Hayashida, M.H. Wu, A. Pierce, A.C. Poncelet, J. Varga, H.W. Schnaper, MAP-kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397, J. Cell Sci. 120 (Pt 23) (2007 Dec 1) 4230–4240 PubMed PMID: 18032789.

[41] A.K. Roseweir, E.S. Halcrow, S. Chichilo, A.G. Powell, D.C. McMillan, P.G. Horgan, J. Edwards, ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer, Br. J. Cancer 119 (3) (2018 Aug) 323–329, https://doi.org/10.1038/s41416-018-0174-y Epub 2018 Jul 10. PubMed PMID: 29988110.

[42] A.K. Roseweir, L. Bennett, A. Dickson, K. Cheng, M.A. Quintayo, J. Bayani, D.C. McMillan, P.G. Horgan, C.J.H. van de Velde, C. Seynaeve, A. Hasenburg, D.G. Kieback, C. Markopoulos, L.Y. Dirix, D.W. Rea, E.A. Mallon, J.M.S. Bartlett, J. Edwards, Predictive biomarkers for endocrine therapy: retrospective study in tamoxifen and Exemestane adjuvant multinational (TEAM) trial, J. Natl. Cancer Inst. 110 (6) (2018 Jun 1) 616–627, https://doi.org/10.1093/jnci/djx255 PubMed PMID: 29917140.